Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Ribo Life Science Acquires Additional 25.93% Stake in Azemidite for RMB 70 Million – Strengthens siRNA Therapeutics Supply Chain

Fineline Cube Jul 1, 2026
Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Fineline Cube Jun 30, 2026
Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Fineline Cube Jun 30, 2026
Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Fineline Cube Jun 30, 2026
Company Deals

Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration

Fineline Cube Jun 30, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

CSPC Innovation Launches Phase III Trial of SYS6010 ADC-PD-1 Combo in Resected NSCLC – Novel EGFR-Targeted Antibody-Drug Conjugate Enters Adjuvant Setting

Fineline Cube Jul 1, 2026
Company Drug

Sanofi Reports Positive Phase 3 Baby-COMET Results for Nexviazyme in Infantile-Onset Pompe Disease – ERT Shows 100% Survival and Ventilation-Free Outcomes at 52 Weeks

Fineline Cube Jul 1, 2026
Company Drug

CIM’s Cancer Vaccine CIMAvax Confirmed Immunogenic in US Study, Cuba Announces

Fineline Cube May 16, 2023

The Cuba-based Molecular Immunology Center (CIM), part of the state-run conglomerate BioCubaFarma, has shared updates...

R&D

COVID-19 Disruptions Lead to Soaring Lab Monkey Prices, Impacting US Drug Development

Fineline Cube May 16, 2023

The COVID-19 pandemic has led to a significant reduction in the export of laboratory monkeys...

Company Drug

Huadong Medicine’s HDM1002 Receives FDA Approval for Clinical Trials

Fineline Cube May 16, 2023

Huadong Medicine Co., Ltd (SHE: 000963), a leading China-based pharmaceutical company, has announced that it...

Company Deals

Rona Therapeutics and Keymed Biosciences Collaborate on siRNA Therapeutics for Glomerulonephritis

Fineline Cube May 15, 2023

China-based Rona Therapeutics Inc. and Keymed Biosciences (HKG: 2162) have unveiled a strategic collaboration aimed...

Company Deals Digital

Omron Healthcare and JD Healthcare Form Partnership to Innovate Chronic Disease Management

Fineline Cube May 15, 2023

At the China International Medical Equipment Fair (CMEF), Omron Healthcare, a leading provider of healthcare...

Company Deals

LaNova Medicines and AstraZeneca Ink Global Licensing Deal for GPRC5D-Targeting ADC LM-305

Fineline Cube May 15, 2023

Shanghai-based LaNova Medicines Ltd, a developer of cancer therapies, has announced a significant global licensing...

Company Deals

ExoRNA Bio Secures Tens of Millions in Financing to Advance Huntington’s Disease Pipeline

Fineline Cube May 15, 2023

ExoRNA Bio, a Shenzhen-based central nervous system (CNS) drug developer, has reportedly raised tens of...

Company Deals

Luye Pharma’s Boan Biotechnology Partners with GenScript on GenCircle dsDNA Development

Fineline Cube May 15, 2023

Shandong Boan Biotechnology Co., Ltd, a controlling subsidiary of China-based Luye Pharma Group (HKG: 2186),...

Company Drug

Betta Pharmaceuticals and EyePoint Pharmaceuticals Submit EYP-1901 for NMPA Review

Fineline Cube May 15, 2023

China’s Betta Pharmaceuticals (SHE: 300558) has announced that the clinical trial filing for its EYP-1901...

Policy / Regulatory

NMPA Releases 68th Batch of Reference Drugs for Generic Quality Consistency Evaluation

Fineline Cube May 15, 2023

The National Medical Products Administration (NMPA) has released the 68th batch of reference drugs for...

Company Medical Device

Basecare Medical to Acquire BMX Holdco for $40 Million, Expanding IVF Portfolio

Fineline Cube May 15, 2023

China-based in vitro fertilization (IVF) specialist, Suzhou Basecare Medical Co., Ltd (HKG: 2170), has announced...

Company Deals

Nona Biosciences Partners with PharmaEssentia for Harnessing Harbor Mice Technology

Fineline Cube May 12, 2023

Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has announced a strategic...

Company Deals

First Condor Biotechnology Secures Tens of Millions in Pre-Series A Financing for CAR-T Cell Trials

Fineline Cube May 12, 2023

First Condor Biotechnology, a Guangdong-based cell therapy developer, has reportedly secured tens of millions of...

Policy / Regulatory

China’s NHC and 13 Bureaus Launch Campaign to Rectify Pharmaceutical and Medical Services Practices

Fineline Cube May 12, 2023

The National Health Commission (NHC) along with 13 other bureaus has jointly released a notification...

Company

Bayer Q1 2023 Financial Report: Sales Dip Amid Regional Challenges and COVID-19 Impact

Fineline Cube May 12, 2023

Germany-based Bayer (ETR: BAYN) has released its financial report for the first quarter of 2023,...

Company Drug

Wuhan Institute’s Hexavalent Rotavirus Vaccine on Track for Priority Review by CDE

Fineline Cube May 12, 2023

The Center for Drug Evaluation (CDE) website has indicated that Wuhan Institute of Biological Products...

Company Drug

Kintor Pharmaceutical’s KX-826 Shows Promise in Phase II Study for Male Androgenetic Alopecia

Fineline Cube May 12, 2023

China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced the conclusion of a randomized, double-blind, placebo-controlled...

Company Deals Digital

ZhenGe Biotech Partners with NNIT for Advanced Digitalization in Drug Development

Fineline Cube May 12, 2023

ZhenGe Biotech, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into a strategic...

Drug Legal / IP

CNIPA Releases Patent Linkage Decisions, Paving Way for Generic Drugs in China

Fineline Cube May 11, 2023

The China National Intellectual Property Administration (CNIPA) has released the latest batch of completed patent...

Company Drug

Guangdong Taienkang’s CKBA Ointment for Vitiligo Accepted for Review by China’s NMPA

Fineline Cube May 11, 2023

Guangdong Taienkang Pharmaceutical Co., Ltd, (SHE: 301263), a China-based pharmaceutical company, has announced that the...

Posts pagination

1 … 549 550 551 … 689

Recent updates

  • CSPC Innovation Launches Phase III Trial of SYS6010 ADC-PD-1 Combo in Resected NSCLC – Novel EGFR-Targeted Antibody-Drug Conjugate Enters Adjuvant Setting
  • Sanofi Reports Positive Phase 3 Baby-COMET Results for Nexviazyme in Infantile-Onset Pompe Disease – ERT Shows 100% Survival and Ventilation-Free Outcomes at 52 Weeks
  • BeOne Medicines Reports 43% Reduction in Disease Progression with BRUKINSA-Rituximab Combo in Phase III MCL Study – Chemotherapy-Free Regimen Shows Significant PFS Benefit
  • Ribo Life Science Acquires Additional 25.93% Stake in Azemidite for RMB 70 Million – Strengthens siRNA Therapeutics Supply Chain
  • METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

CSPC Innovation Launches Phase III Trial of SYS6010 ADC-PD-1 Combo in Resected NSCLC – Novel EGFR-Targeted Antibody-Drug Conjugate Enters Adjuvant Setting

Company Drug

Sanofi Reports Positive Phase 3 Baby-COMET Results for Nexviazyme in Infantile-Onset Pompe Disease – ERT Shows 100% Survival and Ventilation-Free Outcomes at 52 Weeks

Company Drug

BeOne Medicines Reports 43% Reduction in Disease Progression with BRUKINSA-Rituximab Combo in Phase III MCL Study – Chemotherapy-Free Regimen Shows Significant PFS Benefit

Company Deals

Ribo Life Science Acquires Additional 25.93% Stake in Azemidite for RMB 70 Million – Strengthens siRNA Therapeutics Supply Chain

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.